TL;DR: The April 23 rescheduling of medical cannabis to Schedule III delivered the first real relief from Section 280E in the federal tax code’s three-decade grip on the cannabis industry. But for the largest multi-state operators — whose revenues are overwhelmingly adult-use — the more consequential change awaits the outcome of the ongoing DOJ adult-use rescheduling hearings that entered Day 2 on Friday. Analysts estimate that full 280E elimination could add $100–$400 million in combined annual after-tax cash flow across the top five publicly traded MSOs.
Market Analysis
Section 280E of the Internal Revenue Code prohibits businesses that traffic in controlled substances classified in Schedule I or II from deducting ordinary business expenses against federal taxable income. For cannabis companies operating in compliance with state law, this has meant paying federal taxes on gross margin rather than net income — producing effective tax rates of 70% to over 100% for many plant-touching operators, even in years where GAAP net income was negative.
The April 23 rescheduling action moved medical cannabis to Schedule III, carving out a meaningful exception. Operators with significant medical revenue — particularly in states like Florida, Pennsylvania, and Ohio that maintain robust medical programs — began benefiting immediately in Q2 2026 tax planning. For Green Thumb Industries (GTBIF), which generates meaningful revenues across Illinois, Pennsylvania, and New Jersey, the partial relief is real, though limited given the predominance of adult-use in the company’s overall revenue mix.
For Curaleaf Holdings (CURLF), which operates more than 150 retail locations across high-medical-share states, the April action reduced the effective 280E drag at the margin without transforming company economics. Curaleaf management has been among the most explicit in investor communications about the transformative potential of full rescheduling, modeling scenarios where the elimination of 280E could restore multiple percentage points of net margin and shift the company from adjusted EBITDA profitability to meaningful GAAP net income.
Follow sector valuation and pricing at the cannabis stock tracker as the hearing developments unfold through the week.
Regulatory and Market Context
The two-phase structure of the current rescheduling process reflects the legal architecture of the federal Controlled Substances Act. The DEA’s April action reclassified cannabis for medical purposes, drawing on the HHS recommendation submitted in August 2024. The adult-use component required a separate evidentiary hearing under administrative law — the proceedings that began June 25 and continue through this week in Washington.
The hearings’ outcome determines whether cannabis can be formally recognized as having accepted medical use and lower abuse potential independent of whether individual consumers access it through a medical or adult-use channel. Legal scholars and cannabis policy advocates have argued the distinction is artificial in the case of cannabis, where the clinical evidence base has expanded substantially and where 24 states have enacted adult-use frameworks with robust regulatory oversight. If the administrative law judge concurs and the DEA extends Schedule III status to adult-use cannabis, the full 280E burden disappears for all federally compliant operators.
The financial stakes are substantial. Green Thumb Industries has absorbed an estimated $250 million in 280E-related excess taxation over the past three fiscal years. Curaleaf’s equivalent figure has exceeded $300 million over the same period. Collectively, the top five publicly traded MSOs have paid more than $1 billion in excess federal taxes since 2021 — capital that could have been deployed for store expansion, balance sheet repair, or shareholder returns. The magnitude of this deferred benefit explains a significant portion of the Q2 rally in MSOS and individual MSO names.
Conclusion
The cannabis industry is closer to full 280E resolution than at any point in its history, but the finish line is not guaranteed. The DOJ hearing process is formal and methodical, likely extending into Q3 2026 before a proposed rule emerges for public comment — with a final rule following at minimum 60 additional days. Investors who have driven the MSOS sector to 2026 highs are pricing in a high probability of a favorable outcome; the risk premium is now asymmetrically weighted toward the downside if the hearing process stalls or produces an adverse preliminary finding. For now, the direction of regulatory travel remains constructive — and the operators that have paid the most in 280E are best positioned to benefit when the second act finally reaches its conclusion.